It's a little slow on the board today, so I thought I'd post this article abstract I saw the other day. I don't have access to the article. They use the pan-BET inhibitor JQ1, but this may still be a relevant mechanism for the renal protective effects of bromdomain-2 selective apabetalone.
BRD4 contributes to high-glucose-induced podocyte injury by modulating Keap1/Nrf2/ARE signaling
https://www.ncbi.nlm.nih.gov/pubmed/31325480